Witty insists GSK’s safe approach, backed by innovative pipeline, is the way to success

Eric Palmer

GlaxoSmithKline CEO Andrew  continues to take heat for moving the U.K. drugmaker heavier into low-margin areas like consumer health and vaccines. But he continues to insist he has it on the right track, that Glaxo has plenty of new drugs on the way that will be first-in-class and sidestep the high price backlash that some competitors are facing.  


FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS